---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102389"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:51:47.339956+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam Q2 net loss $102.3M; cash $1.2B; BEAM-302 17 patients dosed; BEAM-101 enrollment complete

## Summary
- Net loss of $102.3M ($1.00/share) vs $91.1M loss ($1.11/share) in Q2 2024; R&D expense rose to $101.8M.
- Cash, cash equivalents and marketable securities $1.2B as of June 30, 2025; runway into 2028.
- BEAM-302 Phase 1/2: 17 patients dosed; expanded dose exploration underway; Part B enrollment initiated; data expected early 2026.
- BEAM-101 BEACON trial: 30 SCD patients dosed (adults + first adolescent); updated data expected by end of 2025.
- FDA granted orphan drug designation for BEAM-101 and BEAM-302, and RMAT designation for BEAM-302.

## SEC filing metadata
- accession: 0000950170-25-102389
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017025102389/0000950170-25-102389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017025102389/beam-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102389
- JSON: https://secwatch.observer/filing/0000950170-25-102389.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.